Maker of Risperdal Aggressively Marketed Unapproved Uses of the Drug

Comments (0)

Beginning in 1993, the U.S. Food and Drug Administration (FDA) first approved the use of the antipsychotic drug Risperdal use for the treatment of schizophrenia in adults. Many years later, in 2006 and 2007, the FDA expanded the types of uses that the drug was approved for. Unfortunately, evidence has since come out that shows the drug’s maker may have been illegally and aggressively marketing the use of the drug for unapproved uses. The drug has also been linked to serious adverse side effects in some patients.

5 Allegations of the Aggressive Marketing of Risperdal for Unapproved Uses

What are some of the allegations that are being made against the drug’s manufacturer with regard to the aggressive marketing of Risperdal for unapproved uses? The following is an overview:

  1. Doctors were reportedly given thousands of free samples of the drug.
  2. Sales representatives were assigned sales goals and given incentives in order to encourage them to promote unapproved uses of the drug in elderly dementia patients as well as children suffering from mental disabilities.
  3. The country’s largest pharmacy servicing nursing homes was reportedly paid kickbacks for promoting Risperdal use to doctors treating nursing home patients.
  4. Doctors were reportedly paid to learn about the drug’s unapproved uses as part of an alleged “sham” consulting program.
  5. Doctors were allegedly given rewards to support unapproved uses of Risperdal and increase the number of prescriptions for the drug that they issued. These rewards included lucrative consulting agreements, speaker fees, and retreats at luxury hotels.

Fortunately for victims harmed by the use of Risperdal, various types of compensation for injuries may be available. We encourage you to reach out today for a free consultation at 855-947-0707.


Be the first to comment!

Post a Comment

To reply to this message, enter your reply in the box labeled "Message", hit "Post Message."


Email:* (will not be published)


Notify me of follow-up comments via email.